ACAD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, ACADIA Pharmaceuticals Inc (ACAD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price declines, the stock has strong fundamentals, positive analyst sentiment, and a promising pipeline. The recent pullback appears to be driven by macro factors rather than company-specific issues, presenting a buying opportunity.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral, and moving averages are bearish, suggesting some short-term weakness. The stock is trading near its pivot level of 21.089, with key resistance at 22.034 and support at 20.143.
Analysts have upgraded the stock to 'Buy' with price targets ranging from $29 to $37, citing strong fundamentals, stable sales, and a promising pipeline.
The company's Q4 2025 financials showed significant YoY growth in revenue (+9.39%), net income (+90.32%), and EPS (+84.88%).
The recent 25% pullback is attributed to macro factors, not company-specific issues, presenting a potential buying opportunity.
Insiders are selling, with a 273.71% increase in selling activity over the last month.
The broader market (S&P
is down 1.79%, which may weigh on sentiment.
The stock's moving averages are bearish, indicating short-term weakness.
In Q4 2025, ACADIA Pharmaceuticals reported revenue of $283.99M (+9.39% YoY), net income of $273.57M (+90.32% YoY), and EPS of 1.59 (+84.88% YoY). Gross margin slightly declined to 90.77% (-0.91% YoY). Overall, the financial performance is strong, with significant growth in profitability metrics.
Analysts are broadly positive on ACAD, with recent upgrades to 'Buy' and price targets ranging from $29 to $37. Analysts highlight stable Nuplazid sales, a promising pipeline, and strong guidance for 2026 as key drivers for the stock.
